Every 10-Q that Pacific Biosciences of California, Inc. (PACB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PACB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PACB filings page.
Pacific Biosciences of California, Inc. generated $76.2 M of revenue in the first six months of 2026, roughly flat with 2025, and a gross profit of $25.5 M. Operating loss narrowed sharply to $53.0 M from $473.8 M as prior-year impairment, amortization and restructuring charges rolled off.
Cash, cash equivalents and investments were $236.9 M at June 30, 2026, down from $279.5 M at year-end after substantial operating cash outflows, partly offset by $48.1 M of net proceeds from selling short-read sequencing assets to Illumina Cambridge Limited. Convertible notes outstanding remain significant, and stockholders’ equity moved to a deficit.
The company settled patent litigation with Personal Genomics of Taiwan through a license and a $21.4 M payment obligation, and approved a July 2026 restructuring expected to cut annual operating expenses by $30–40 M via an approximately 8% workforce reduction. Mark Van Oene will become CEO on August 5, 2026 as PacBio continues emphasizing its HiFi long-read Revio and Vega platforms.
Pacific Biosciences of California, Inc. reported Q1 2026 revenue of $37.2 million, essentially flat year over year, with higher consumable sales offsetting softer instrument and service revenue. Revio system placements rose while Vega unit volumes and pricing were pressured by promotions and funding constraints.
Gross profit improved to $12.8 million from a gross loss of $1.4 million a year earlier as cost of revenue declined sharply. The company posted a much smaller net loss of $8.3 million versus $426.1 million in Q1 2025, largely because the prior period included large one-time amortization and impairment charges and the current quarter benefited from a $45.8 million gain on an asset sale to Illumina.
Cash, cash equivalents and investments totaled $276.0 million as of March 31, 2026, only slightly below year-end. PacBio highlights continued restructuring-driven operating expense reductions, a new license and settlement agreement with PGI that creates fixed payments through 2029, and an ongoing focus on driving HiFi sequencing adoption via the Revio and Vega platforms and upcoming SPRQ-Nx consumables.
Pacific Biosciences (PACB) filed its quarterly report, highlighting restructuring impacts and continued losses. Q3 revenue was $38.4 million versus $40.0 million a year ago, while gross profit improved to $15.9 million. Operating loss narrowed to $38.9 million from $64.1 million as cost of revenue declined.
Year to date, the company recorded a net loss of $506.0 million, driven primarily by $359.3 million of accelerated amortization tied to discontinued short-read development and a $15.0 million IPR&D impairment. Stockholders’ equity fell to $36.1 million from $506.6 million at year-end. Cash and investments totaled $298.7 million as of September 30, including $56.5 million in cash. Operating cash outflow was $92.1 million for the nine months. Convertible notes totaled $645.2 million (net), including the 2029 and 2030 notes; contingent consideration from the Apton deal was reduced to $0. Shares outstanding were 301,907,431 as of October 31, 2025.